Abstract

This study aimed to investigate the impact of the luteolin-microRNA-335-3p pathway on the proliferation and osteogenic differentiation of bone marrow mesenchymal stem cells. Cell proliferation was assessed using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide assay and osteogenic markers were assayed by Western blotting. Luteolin treatment demonstrated a dose-dependent promotion of bone marrow mesenchymal stem cells proliferation, accompanied by an increase in osteogenic marker content within the cells. Additionally, luteolin treatment dose-dependently up-regulated microRNA-335-3p levels. The restoration of microRNA-335-3p further augmented bone marrow mesenchymal stem cells proliferation and up-regulated osteogenic differentiation markers. Conversely, knockdown of microRNA-335-3p negated the promoting effects of luteolin on bone marrow mesenchymal stem cells. Luteolin facilitates osteogenic differentiation and proliferation in bone marrow mesenchymal stem cells by elevating microRNA-335-3p. This molecular pathway holds promise as a potential therapeutic target for enhancing bone regeneration and combating bone-related disorders.